One of the most common questions parents ask: "Will my child need to take this forever?" It's a fair question, and the honest answer is nuanced.
GLP-1 medications address the biological drivers of obesity - but they don't cure the underlying condition. When medication is discontinued, the hormonal signals it was correcting can return. Understanding this helps families make informed decisions about treatment duration and planning.
What the research shows
Studies in adults show that after discontinuing GLP-1 medication without ongoing support, a significant portion of weight lost can return within 12 months. The STEP 1 extension trial found that participants regained approximately two-thirds of their weight loss after stopping semaglutide.
However, this data comes primarily from adults who discontinued medication without structured lifestyle support. The adolescent picture is more complex, and potentially more optimistic, for several reasons:
- Adolescents are still developing habits. Interventions during this period can create lasting behavioral patterns
- Growth and development continue, which can shift the BMI trajectory even after medication stops
- Comprehensive programs that build lifestyle skills alongside medication may produce more durable results
- Earlier intervention means less metabolic damage to reverse
Why lifestyle support changes the equation
The key variable in discontinuation outcomes isn't the medication; it's what was built alongside it. Families who use the treatment period to establish sustainable nutrition habits, regular physical activity, and behavioral skills tend to maintain more of their progress.
This is precisely why Thryvwell integrates behavioral support and nutrition guidance from day one. The medication creates a window of opportunity (reduced hunger, improved energy, early success), and the support fills that window with lasting skills.
Think of it this way: the medication makes change possible. The support makes change permanent.
Wondering if this applies to your child? The 2-minute eligibility check tells you if Thryvwell could be a fit. No commitment, no payment info.
How Thryvwell approaches discontinuation
We don't treat discontinuation as an afterthought. From the beginning of treatment, the clinical team is building toward sustainability:
The bottom line
Obesity is a chronic condition. For some adolescents, longer-term medication may be appropriate, just as it is for other chronic conditions like asthma or ADHD. For others, a defined treatment period combined with strong lifestyle foundations can produce lasting results without ongoing medication.
The goal isn't to keep your child on medication forever. The goal is to give their body the support it needs, for as long as it needs it, while building the skills and habits that carry them forward.
Sources
- Wilding, J.P.H. et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes, Obesity and Metabolism (2022)
- American Academy of Pediatrics. Clinical Practice Guideline for Obesity Treatment (2023)
- Rubino, D. et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo." JAMA (2021)
Questions about treatment duration?
Our clinical team discusses long-term planning with every family from the start
The information on this page is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any treatment.
